HighlightsThe article describes the main pathogenetic aspects of atherogenesis and focuses on the role of low-intensity inflammation in this process. Moreover, the article presents data on the possibilities of predicting cardiovascular outcomes in patients using a number of pro-inflammatory markers, and on the effectiveness of anti-inflammatory therapy in this cohort of patients. AbstractChronic low-intensity inflammation is currently considered one of the most significant risk factors for cardiovascular disease. The initiation and progression of atherosclerosis are associated with an inflammatory response to endothelial damage, accompanied by an increase in number of pro-inflammatory markers blood circulation. The atherogenic effect of the main risk factors for atherosclerosis, such as hypertension, smoking, increased dietary fat intake, physical inactivity and obesity, as well as psychological and emotional factors and sleep disturbance, is mostly carried out through these mechanisms. In addition, proinflammatory cytokines blood levels increase is associated with sympathetic tone level increase under these risk factors influence.The article describes the relevant atherogenesis mechanisms and the results of large clinical trials studying the relationship between inflammatory activity, assessed by the levels of various pro-inflammatory markers, and the risk of cardiovascular complications. Data regarding the use of anti-inflammatory drugs such as canakinumab, anakinra, tocilizumab, colchicine to treat patients with coronary artery disease are given. The efficacy of nano-immunotherapy, when powerful anti-inflammatory agents are target delivered to atherosclerotic plaques using nanoparticles, is considered, as well as the anti-inflammatory effect of renal denervation due to the sympatholytic activity of this procedure.